Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement ...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored ...
RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the Re ...
GlobalData on MSN17h
Macau approves IASO Bio’s multiple myeloma therapy
The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new ...
Knowridge Science Report23h
“Forever chemical” linked to liver cancer, study finds
Scientists from the University of Southern California (USC) have discovered a link between exposure to a common synthetic ...
European Medical Journal16h
Gene Therapy Shows Promise for Liver Disease Treatment
Discover a recent first-in-human gene therapy trial that has shown promising results in improving glucose homeostasis.